7.96
price down icon1.97%   -0.16
after-market Handel nachbörslich: 7.80 -0.16 -2.01%
loading
Schlusskurs vom Vortag:
$8.12
Offen:
$8.06
24-Stunden-Volumen:
113.73K
Relative Volume:
0.44
Marktkapitalisierung:
$253.99M
Einnahmen:
$128.45M
Nettoeinkommen (Verlust:
$6.54M
KGV:
159.20
EPS:
0.05
Netto-Cashflow:
$-8.79M
1W Leistung:
-3.86%
1M Leistung:
+17.58%
6M Leistung:
+7.13%
1J Leistung:
+68.64%
1-Tages-Spanne:
Value
$7.87
$8.06
1-Wochen-Bereich:
Value
$7.87
$8.6299
52-Wochen-Spanne:
Value
$3.6793
$8.6299

Lifecore Biomedical Inc Stock (LFCR) Company Profile

Name
Firmenname
Lifecore Biomedical Inc
Name
Telefon
(952) 368-4300
Name
Adresse
3515 LYMAN BOULEVARD, CHASKA
Name
Mitarbeiter
524
Name
Twitter
Name
Nächster Verdiensttermin
2025-04-03
Name
Neueste SEC-Einreichungen
Name
LFCR's Discussions on Twitter

Vergleichen Sie LFCR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
LFCR
Lifecore Biomedical Inc
7.96 253.99M 128.45M 6.54M -8.79M 0.05
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
14.60 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.19 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.35 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.37 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.64 20.17B 16.54B -1.64B 749.00M -1.45

Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-21 Eingeleitet William Blair Outperform
2024-09-05 Eingeleitet Craig Hallum Buy
2024-08-28 Herabstufung Barrington Research Outperform → Mkt Perform
2023-03-20 Herabstufung Stephens Overweight → Equal-Weight

Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten

pulisher
Jun 18, 2025

Lifecore Biomedical: Inflecting Financials Over Next 3 Years (NASDAQ:LFCR) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore signs 10-year manufacturing deal with key ophthalmic client By Investing.com - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Enters 10-Year Commercial Manufacturing & Supply Agreement with Existing Customer - Contract Pharma

Jun 17, 2025
pulisher
Jun 17, 2025

2025-06-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect | NDAQ:LFCR | Press Release - Stockhouse

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore signs 10-year manufacturing deal with key ophthalmic client - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophth - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Signs 10-Year Manufacturing, Supply Deal With Ophthalmic Therapy Customer - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophthalmic Therapy | LFCR Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Signs 10-Year Commercial Manufacturing Agreement to Advance Novel Ophthalmic Therapeutic - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Lifecore Biomedical Lands Multi-Million Dollar, 10-Year Manufacturing Contract for Novel Eye Treatment - Stock Titan

Jun 17, 2025
pulisher
Jun 15, 2025

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Purchased by Bank of America Corp DE - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale - MSN

Jun 14, 2025
pulisher
Jun 12, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore receives early $10 million payment for equipment sale By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale - GlobeNewswire

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore Receives Full Payment Early For $17 Mln Equipment Sale - Nasdaq

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore Biomedical Receives Remaining $10 Million for Sale of Isolator Filler Ahead of Schedule - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore (LFCR) Completes $10 Million Equipment Sale Payment | LFCR Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore receives early $10 million payment for equipment sale - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Lifecore Biomedical Fast-Tracks $10M Equipment Payment as New Filler Promises $300M Revenue Potential - Stock Titan

Jun 12, 2025
pulisher
Jun 10, 2025

2025-06-10 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse

Jun 10, 2025
pulisher
Jun 10, 2025

Squarepoint Ops LLC Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

(LFCR) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 08, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 05, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

Contrasting Lifecore Biomedical (NASDAQ:LFCR) & Liquidia (NASDAQ:LQDA) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

How the (LFCR) price action is used to our Advantage - news.stocktradersdaily.com

May 28, 2025
pulisher
May 27, 2025

Lifecore appoints new chief commercial officer to drive growth By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Lifecore Biomedical Appoints CCO - Contract Pharma

May 27, 2025
pulisher
May 27, 2025

Lifecore Biomedical Names Mark Dafonseca Chief Commercial Officer - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

LFCR Appoints New Chief Commercial Officer | LFCR Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Lifecore appoints new chief commercial officer to drive growth - Investing.com

May 27, 2025
pulisher
May 27, 2025

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Lifecore Biomedical Taps 30-Year Pharma Veteran as CCO to Accelerate CDMO Market Expansion - Stock Titan

May 27, 2025
pulisher
May 27, 2025

Northern Trust Corp Purchases 28,019 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World

May 27, 2025
pulisher
May 24, 2025

Analysts Set Expectations for LFCR Q4 Earnings - Defense World

May 24, 2025
pulisher
May 23, 2025

William Blair Begins Coverage on Lifecore Biomedical (NASDAQ:LFCR) - Defense World

May 23, 2025
pulisher
May 22, 2025

What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies? - Insider Monkey

May 22, 2025
pulisher
May 21, 2025

Lifecore Biomedical (LFCR) Receives 'Outperform' Rating from Wil - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Lifecore stock gains on Outperform rating by William Blair - Investing.com Canada

May 21, 2025

Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lifecore Biomedical Inc-Aktie (LFCR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
English Aron R.
10% Owner
May 28 '25
Sale
7.12
150,419
1,071,555
264,180
English Aron R.
10% Owner
May 23 '25
Sale
6.75
96,137
649,386
1,554,103
English Aron R.
10% Owner
May 13 '25
Sale
7.00
12,334
86,353
1,650,240
English Aron R.
10% Owner
May 12 '25
Sale
7.03
45,698
321,426
1,662,574
English Aron R.
10% Owner
May 08 '25
Sale
7.00
5,098
35,693
1,708,972
English Aron R.
10% Owner
May 09 '25
Sale
7.00
700
4,900
1,708,272
English Aron R.
10% Owner
May 05 '25
Sale
7.08
24,543
173,831
1,730,618
English Aron R.
10% Owner
May 07 '25
Sale
7.01
15,847
111,099
1,714,070
English Aron R.
10% Owner
May 06 '25
Sale
7.05
701
4,940
1,729,917
Josephs Paul
Chief Executive Officer
Jan 08 '25
Buy
5.74
17,000
97,580
559,717
$14.43
price up icon 1.05%
$9.18
price up icon 2.80%
$128.00
price up icon 1.84%
$290.91
price up icon 1.24%
drug_manufacturers_specialty_generic RDY
$14.94
price down icon 0.60%
$16.64
price down icon 0.72%
Kapitalisierung:     |  Volumen (24h):